ALENDRONATE FOR GLUCOCORTICOID-ASSOCIATED OSTEOPENIA

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该试验将检验以下假设：在患有克罗恩病、溃疡性结肠炎、全身性幼年类风湿性关节炎和幼年皮肌炎的儿童和青少年中，用18个月的阿仑膦酸盐（FOSAMAX，Merck & Co.，Inc.）与18个月的标准治疗相比，通过双能X线吸收测定法（DXA）测定的个体AP脊柱BMD（gm/cm）的平均变化将得到更大的改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This trial will test the hypothesis that among children and adolescents with Crohn's disease, ulcerative colitis, systemic-onset juvenile rheumatoid arthritis and juvenile dermatomyositis, treatment of glucocorticoid-associated osteopenia and osteoporosis with 18 months of alendronate (FOSAMAX, Merck & Co., Inc.) will result in greater improvement in mean changes in individual AP spine BMD (gm/cm) determined by dual energy X-ray absorptiometry (DXA) than treatment with 18 months of standard care therapy.